Loading
Nordhealth AS Stock: price and insider trades · Norway
No insider purchase over the last 90 days. The latest was filed 28 Jun 2023.
Nordhealth AS: what insiders have been doing
Nordhealth AS is a Health Care company. Its directors and officers file their transactions with Oslo Børs. In the past year (18 October 2025 to 18 October 2026), 6 filings came from 2 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
No insider has bought Nordhealth AS shares on the open market in the past twelve months.
Compared with its exchange (258 companies, median 4 filings), a count of 6 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 16 purchases and 1 sale.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by Oslo Børs. They describe what insiders did and are not a recommendation.
Insider Decl.
36
Thresholds
n/a
Buy Volume
€6M
16 ops. · all time
Sell Volume
n/a
1 ops. · all time
Since the insiders bought
- +25.5%Entry NOK 25.10 · Close at T+365 NOK 31.50
- +23.4%Entry NOK 25.20 · Close at T+365 NOK 31.10
- +49.1%Entry NOK 23.40 · Close at T+365 NOK 34.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Nordhealth AS Strong Buy (bullish), based on 1 analysts. Average price target: NOK 32.43.
Fundamental score
Ranked 18,063 of 24,148 companies
34.8
score / 100
Value33
Quality37
FCF yld-0.2%
Earn yld-0.6%
EV/EBITDA·
ROE-26%
Gross mgn81%
Net mgn-25%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NOK 26.80
Analyst consensus
1 analystsStrong buy
NOK 32.43Target NOK 32.43(+21%)NOK 32.43
Income statement
RevenueNOK 50.8M
Gross profitNOK 41.3M81% margin
EBITDA-NOK 965k-2% margin
Net income-NOK 12.7M-29.9% margin
Valuation
PER (forward)446.7x
P/Book3.6x
Beta0.33
Balance sheet & cash
Market capNOK 2.1B
Free Cash Flow-NOK 4.4M
Profitability & ownership
ROE-25.8%
ROA-12.6%
% insiders6.2%
% institutions8.9%
Last declaration on 30 September 2026
Declarations36 total
ShareMERKOSLO:683368
ShareMERKOSLO:683103
ShareMERKOSLO:669675
ShareMERKOSLO:669432
ShareMERKOSLO:667745
ShareMERKOSLO:662188
OptionMERKOSLO:656441
ShareMERKOSLO:654983
ShareMERKOSLO:653338
ShareMERKOSLO:648686
ShareMERKOSLO:648372
ShareMERKOSLO:648294
ShareMERKOSLO:648046
@ €3.0128ShareMERKOSLO:646368
@ €2.3379ShareMERKOSLO:614213
ShareMERKOSLO:607792
@ €1.8863ShareMERKOSLO:607479
ShareMERKOSLO:604275
@ €2.003ShareMERKOSLO:604259
@ €2.1255ShareMERKOSLO:594307
Canonical exit: 26 Sept 2023 (T+90)
@ €2.2455ShareMERKOSLO:593535
Canonical exit: 14 Sept 2023 (T+90)
@ €1.9389ShareMERKOSLO:591816
Canonical exit: 24 Aug 2023 (T+90)
@ €1.8546ShareMERKOSLO:591708
Canonical exit: 23 Aug 2023 (T+90)
@ €1.8546ShareMERKOSLO:591603
Canonical exit: 23 Aug 2023 (T+90)
@ €1.8385ShareMERKOSLO:591436
Canonical exit: 22 Aug 2023 (T+90)
25 of 36 declarations
About Nordhealth AS
Nordhealth AS is a company operating in the health and pharmaceutical sector, listed on the XOSL market. It focuses on developing digital solutions to enhance healthcare.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
